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Abstract
Xenotropic murine leukemia virus-related virus (XMRV) is a retrovirus implicated in prostate cancer and chronic
fatigue syndrome (CFS). Press releases have suggested that it could contribute to autism spectrum disorder (ASD).
In this study we used two PCR assays and one antibody assay to screen 25 blood samples from autistic children
born to mothers with CFS and from 20 mixed controls including family members of the children assayed, people
with fibromyalgia and people with chronic Lyme disease. Using a real-time PCR assay, we screened an additional
48 South Carolina autism disorder samples, 96 Italian ASD samples, 61 South Carolina ASD samples and 184
healthy controls. Despite having the ability to detect low copy number XMRV DNA in a large background of
cellular DNA, none of the PCR assays found any evidence of XMRV infection in blood cells from patients or
controls. Further, no anti-XMRV antibodies were detected, ruling out possible low level or abortive infections in
blood or in other reservoirs. These results imply that XMRV is not associated with autism.
Findings
Xenotropic murine leukemia virus-related virus (XMRV)
is a recently discovered retrovirus that can infect humans
[1]. Studies of the virus in prostate cancer have given con-
flicting results, with between 0% and 27% of prostate can-
cers suggested to be associated with XMRV [2-4]. More
recently, Lombardi, et al showed that 67% of people with
chronic fatigue syndrome (CFS) were positive for XMRV
by PCR amplification of the gag gene [5]. In an interview
given on the same day as the Lombardi publication,
Dr Mikovits stated that they had found XMRV in a ‘signif-
icant number’ of autism spectrum disorder (ASD) samples
and speculated that ‘this might even explain why vaccines
lead to autism in some children’ [6]. Shortly thereafter,
widely circulated articles appeared, containing non-peer
reviewed data with reports that XMRV may be present in
≥40% of people with autism [7]. Given the recent contro-
versy over the connection between ASD and the MMR
(measles, mumps, rubella) vaccine, a scientific evaluation
of these statements is important [8,9]. ASD comprises
multiple cognitive and developmental disorders, including
autistic disorder (AD), Asperger disorder and PDD-NOS
(pervasive developmental disorder, not otherwise speci-
fied). Although ASD affects an estimated 1 in every 110
individuals, no consistent causes for the disease have been
identified [10].
In this study, we screened for a link between XMRV and
autism. First, we looked for XMRV in 25 blood samples
from children with ASD born to mothers with CFS and in
20 samples from a mix of controls including healthy family
members of the children, people with fibromyalgia and
people with chronic Lyme disease. We also assayed geno-
mic DNA from 96 Italian ASD samples, 48 South Carolina
AD samples, 61 South Carolina ASD samples and 184
healthy controls for presence of XMRV DNA. The healthy
controls were a mix of healthy male and female college
students and newborns from South Carolina.
A novel real-time PCR assay targeting the pol gene in
murine leukemia virus (MuLV) and XMRV was used to
detect XMRV (Table 1). The primers and probes for the
assay were designed against regions of XMRV that were
100% conserved in the seven sequenced XMRV strains
(available in GenBank; accession numbers GQ497344.1,
GQ497343.1, NC_007815.1, EF185282.1, DQ399707.1,
DQ241302.1, DQ241301.1). The pol assay targets a con-
served region in murine leukemia viruses, allowing the
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tivity of the assay was determined by running dilutions
(600, 60 and 6 copies per reaction) of synthetic DNA of
the VP62 XMRV strain in a background of 2.5 μgo f
genomic DNA. DNA from XMRV-infected 22Rv1 cells
was used as an additional validation of the sensitivity of
each assay [11]. Dilutions of 1000, 100 and 10 pg were
used in a background of 2.5 μg of genomic DNA.
Assuming 6 pg/cell, these dilutions correspond to 170,
17 and 1.7 infected cells per reaction.
Samples were obtained from the autistic children of
mothers with CFS and from banked, well-characterized
autism samples at the Greenwood Genetic Center.
Informed consent was obtained from all participants or
legally authorized representatives and identifying infor-
mation was removed from each sample. For the former
cohort, blood was collected, and the buffy coat was
immediately isolated for nucleic acid extraction (Blood
DNA Minikit; Qiagen, Valencia, CA, USA). Plasma sam-
ples were frozen for later analysis. Extracted DNA was
quantified on a spectrophotometer (Nanodrop; Thermo
Scientific, Wilmington, DE, USA) and checked for integ-
rity with a minimum 260:280 ratio of 1.8. DNA was
diluted to 100 ng/μl. For the latter cohort and the healthy
controls, DNA was extracted from blood using proteinase
K lysis and high-salt precipitation as previously described
[12]. For the samples from autistic children born to
mothers with CFS, 25 μl of sample (2.5 μgo fD N Aa n d
833 ng of peripheral blood mononuclear cell (PBMC)
DNA) were added to 25 μl of a commercial master mix
(Simplex DNA Master Mix; Cooperative Diagnostics,
Greenwood, SC, USA) with a final primer concentration
of 250 nmol/l and probe concentration of 200 nmol/l.
The 25 ASD samples from children born to mothers with
CFS and the 20 mixed control samples were also sub-
mitted to the Centers for Disease Control (CDC) for
blinded assaying using an XMRV western blot and a
nested PCR assay (external primers XPOLOF and
XPOLOR; internal primers XPOLIF and XPOLIR as
shown in the Switzer, et al publication) that detects both
MuLV and XMRV pol gene sequences [13]. The CDC
nested PCR assay used 1.0 μg of DNA and was capable of
detecting < 10 copies of VP62 XMRV DNA. The DNA
integrity of the samples was verified by b-actin PCR as an
internal control, as describedp r e v i o u s l y[ 1 3 ] .T h ew e s -
tern blot used denatured XMRV as antigen, which was
crossreactive with anti-MuLV-positive goat sera for the
envelope (glycoprotein (gp)69/71), transmembrane
(p15E), matrix (p15), Gag (pr68) and capsid (p30) anti-
gens. For the banked samples and healthy controls, 5 μl
of sample (500 ng of DNA and 167 ng of PBMC DNA)
were added to 5 μl of a master mix (Simplex DNA Mas-
ter Mix; Cooperative Diagnostics) with primer and probe.
Real-time PCR cycling conditions were 95°C for 20 sec-
onds followed by 45 cycles of 95°C for 1 second and 60°C
for 20 seconds. Two positive controls (10 pg of XMRV
infected 22Rv1 cell DNA or 60 copies of VP62 XMRV
synthetic DNA spiked into 2.5 μg of genomic DNA) and
two negative controls (nuclease-free water) were included
in each run.
The pol real-time PCR assay was able to detect
XMRV DNA extracted from infected 22Rv1 cells in a
background of 2.5 μgD N A( 8 3 3n gP B M CD N A ) ,
increasing the sensitivity 10 to 25 times if that described
by Lombardi et al. (Figure 1) [5]. The CDC PCR assay
was capable of detecting < 10 copies of XMRV in a
background of 1 μg genomic DNA. However, after ana-
lyzing the samples from 25 autistic children born to
mothers with CFS and 20 mixed controls, there was no
evidence of XMRV infection in any of the PCR assays
(Table 2). No anti-XMRV antibodies were detected in
these samples either, ruling out low-level infections that
might have been missed by PCR. Additional assaying of
AD, ASD and healthy control samples by real-time PCR
revealed no evidence of XMRV infection. In all, 230
autism samples and 204 controls gave negative PCR
results for XMRV.
In detection of any new virus, false positives and false
negatives are always a concern. In this case, the ability
to detect low copy numbers of XMRV by two different
PCR assays, both designed to recognize regions of
XMRV/MuLV that are 100% conserved in all published
XMRV strains, implies that the assays would be able to
detect XMRV if it was present in the samples. It is pos-
sible that XMRV was present in the samples at levels
below the detection limit of the PCR assays, but this
seems unlikely given the relatively high frequency of
infection found by Lombardi et al. in people with CFS
using a much smaller amount of sample [5]. The sam-
ples could have inhibited the PCR assay, but this is unli-
kely as XMRV DNA spiked into random patient
samples was readily detected in every case. Further, no
Table 1 Real-time PCR primer and probe sequences for
the pol xenotropic murine leukemia virus-related virus
(XMRV) assay
Name Sequence (5’®3’)
1
pol (2794 to 3062)
Primers
Forward GGGGATCAAGCCCCACATA
Reverse GGTGGAGTCTCAGGCAGAAAA
Probe
[6FAM] TGTTCCAGGGGGACTGGCAAGGTAC
CAccctgg [DABC]
2,3
1Reference sequence was the VP62 XMRV strain (GenBank: EF185282.1).
2Lower case bases were added to form the stem.
3[6FAM] and [DABC] are the fluorophore FAM and the quencher Dabcyl,
respectively.
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possibility of low-level or abortive infections in blood or
other reservoirs that the PCR assay might have missed.
The presence of false positives in the CFS-XMRV
findings cannot be ruled out, and it is supported by the
following observations. A previous attempt to validate
the findings of Lombardi et al. [5] found no XMRV in
186 CFS samples [14]. A second independent attempt
also failed to find any association between XMRV and
CFS, using both PCR and XMRV antibody assays in the
170 CFS samples assayed [15]. A third attempt in the
Netherlands also failed to find XMRV in 32 CFS sam-
ples [16], and a fourth attempt in the US also failed to
find XMRV in 51 CFS samples [13].
Another interesting differentiator between our data
and previous results is the lack of evidence of PCR-
detectable XMRV in the blood of healthy controls. The
Lombardi et al. study showed that in addition to 67% of
people with CFS having PCR-detectable levels of XMRV
in the blood, there may be a baseline of infection within
the general population that is as high as 4% [5]. The
three European studies, all of which failed to find evi-
dence of XMRV in the blood of controls or CFS sam-
ples, seem to suggest that the 4% rate detected by
Lombardi et al. is much greater than the actual preva-
lence in the world, and may have been inflated by either
geographically confined assaying or false positives
[14-16]. Our results confirm that suggestion; we found
no evidence of XMRV in 204 controls and 230 autism
samples (434 samples in total).
From the results presented here, if XMRV is present in
people with autism, it is an extremely rare occurrence and
is unlikely to be a significant contributor to the disorder.
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Figure 1 Absence of Xenotropic murine leukemia virus-related virus (XMRV) in autism using real-time PCR. (A) XMRV pol gene detection
of dilutions of XMRV DNA extracted from infected 22Rv1 cells (170, 17, 1.7 and 0 cells, assuming 6 pg DNA per cell) in a background of 2.5 μg
DNA. (B) Typical results for autism samples using pol gene real-time PCR with a positive control of XMRV DNA from 1.7 infected 22Rv1 cells in a
background of 2.5 μg DNA. There were no positives other than the positive control.
Table 2 Results of xenotropic murine leukemia virus-
related virus (XMRV) real-time PCR
Sample Positives by assay
1
pol CDC
2 pol WB
Autistic children of mothers with CFS
3 0/25 0/24 0/25
Mixed controls 0/20 0/19 0/20
Italian ASD
4 0/96
South Carolina autism disorder 0/48
South Carolina ASD 0/61
Newborn healthy controls 0/96
Male healthy controls 0/88
Totals 0/434 0/43 0/45
1Shows number of samples assayed and number of positives, including results
for pol, CDC pol genes and a western blot (WB) for detection of anti-XMRV
antibodies.
2CDC, Centers for Disease Control.
3CFS, chronic fatigue syndrome.
4ASD, autism spectrum disorder.
Satterfield et al. Molecular Autism 2010, 1:14
http://www.molecularautism.com/content/1/1/14
Page 3 of 4Author details
1Cooperative Diagnostics, LLC, Greenwood, SC 29646, USA.
2Institute of
Medical Genetics, Catholic University, Rome, Italy.
3Greenwood Genetic
Center, Greenwood, SC 29646, USA.
Authors’ contributions
BCS and RAG designed the XMRV assay. CES and BCS planned the
experiments, and RAG ran the assays. BCS wrote the paper. CES and FG
contributed samples and expertise surrounding autism.
Competing interests
BCS and RAG are employees of Cooperative Diagnostics. Cooperative
Diagnostics is a commercial enterprise that owns the rights to the XMRV
real-time PCR assay described in this manuscript, in addition to the Master
Mix that was used. Publication of these results may well reduce the
potential market that Cooperative Diagnostics could reach with its XMRV
assay.
Received: 14 May 2010 Accepted: 14 October 2010
Published: 14 October 2010
References
1. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K,
Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL: Identification
of a novel gammaretrovirus in prostate tumors of patients homozygous
for R462Q RNASEL variant. PLoS Pathog 2006, 2:e25.
2. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR: XMRV is present in
malignant prostatic epithelium and is associated with prostate cancer,
especially high-grade tumors. Proc Natl Acad Sci USA 2009,
106:16351-16356.
3. Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N, Denner J,
Miller K, Kurth R, Bannert N: Lack of evidence for xenotropic murine
leukemia virus-related virus(XMRV) in German prostate cancer patients.
Retrovirology 2009, 6:92.
4. Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H, Aepfelbacher M,
Schlomm T: Prevalence of human gammaretrovirus XMRV in sporadic
prostate cancer. J Clin Virol 2008, 43:277-283.
5. Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, Peterson DL,
Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Silverman RH,
Mikovits JA: Detection of an infectious retrovirus, XMRV, in blood cells of
patients with chronic fatigue syndrome. Science 2009, 326:585-589.
6. Mikovits JA, Whittemore A: Interview with Sam Shad. Nevada Newsmakers
2009.
7. Kirby D: Is autism associated with a viral infection? The Huffington Post
2009 [http://www.huffingtonpost.com/david-kirby/is-autism-associated-
with_b_316986.html].
8. Retraction-Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and
pervasive developmental disorder in children. Lancet 1998, 375:445.
9. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M,
Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE,
Walker-Smith JA: Ileal-lymphoid-nodular hyperplasia, non-specific colitis,
and pervasive developmental disorder in children. Lancet 1998,
351:637-641.
10. Autism and Developmental Disabilities Monitoring Network Surveillance
Year 2006 Principal Investigators; Centers for Disease Control and
Prevention (CDC): Prevalence of autism spectrum disorders - Autism and
Developmental Disabilities Monitoring Network, United States, 2006.
MMWR Surveill Summ 2009, 58:1-20.
11. Knouf EC, Metzger MJ, Mitchell PS, Arroyo JD, Chevillet JR, Tewari M,
Miller AD: Multiple integrated copies and high-level production of the
human retrovirus XMRV (xenotropic murine leukemia virus-related virus)
from 22Rv1 prostate carcinoma cells. J Virol 2009, 83:7353-7356.
12. Schwartz CE, Ulmer J, Brown A, Pancoast I, Goodman HO, Stevenson RE:
Allan-Herndon syndrome. II. Linkage to DNA markers in Xq21. Am J Hum
Genet 1990, 47:454-458.
13. Switzer WM, Jia H, Hohn O, Zheng H, Tang S, Shankar A, Bannert N,
Simmons G, Hendry RM, Falkenberg VR, Reeves WC, Heneine W: Absence
of evidence of xenotropic murine retrovirus-related virus infection in
persons with chronic fatigue syndrome and healthy controls from the
United States. Retrovirology 2010, 7:57.
14. Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D, Wessely S,
Cleare A: Failure to detect the novel retrovirus XMRV in chronic fatigue
syndrome. PLoS One 5:e8519.
15. Groom HC, Boucherit VC, Makinson K, Randal E, Baptista S, Hagan S,
Gow JW, Mattes FM, Breuer J, Kerr JR, Stoye JP, Bishop KN: Absence of
xenotropic murine leukaemia virus-related virus in UK patients with
chronic fatigue syndrome. Retrovirology 2010, 7:10.
16. van Kuppeveld FJ, de Jong AS, Lanke KH, Verhaegh GW, Melchers WJ,
Swanink CM, Bleijenberg G, Netea MG, Galama JM, van der Meer JW:
Prevalence of xenotropic murine leukaemia virus-related virus in
patients with chronic fatigue syndrome in the Netherlands: retrospective
analysis of samples from an established cohort. BMJ 340:c1018.
doi:10.1186/2040-2392-1-14
Cite this article as: Satterfield et al.: PCR and serology find no
association between xenotropic murine leukemia virus-related virus
(XMRV) and autism. Molecular Autism 2010 1:14.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Satterfield et al. Molecular Autism 2010, 1:14
http://www.molecularautism.com/content/1/1/14
Page 4 of 4